PACS Group, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; financial statements are unaudited. PACS operates skilled nursing and assisted living facilities and related real estate businesses. At quarter-end, it operated 218 facilities across nine states, with approximately 24,320 skilled nursing beds and 860 assisted living beds. Comparisons below are with Q1 2023 unless otherwise noted.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior date | Change |
|---|---|---|---|
| Total revenue | $934.7 million | $708.4 million | +31.9% |
| Operating income | $80.0 million | $59.3 million | +34.9% |
| Net income | $49.1 million | $37.6 million | +30.7% |
| Diluted EPS | $0.38 | $0.29 | +$0.09 |
| Operating margin | 8.6% | 8.4% | +0.2 percentage points |
| Net margin | 5.3% | 5.3% | Broadly unchanged |
| Net cash from operating activities | $58.8 million | $79.3 million | Down $20.5 million |
| Cash, cash equivalents and restricted cash | $93.3 million | $134.9 million | Down $41.6 million |
Cost of services increased 36.6% to $736.0 million and rent expense increased 41.8% to $64.0 million, both faster than revenue. General and administrative expense fell 21.1% to $46.9 million, primarily reflecting lower professional and general liability insurance costs and fewer acquisition-related costs. Interest expense rose 44.7% to $15.4 million. A $8.0 million gain on lease termination contributed to reported earnings; it is excluded in the company’s Adjusted EBITDA reconciliation.
EBITDA was $96.3 million versus $65.6 million; Adjusted EBITDA was $88.5 million versus $66.1 million. Adjusted EBITDAR was $152.5 million in Q1 2024; the filing does not provide a comparative Q1 2023 figure in the reconciliation shown.
At March 31, 2024, cash and cash equivalents were $81.2 million, current assets $831.7 million and current liabilities $531.5 million. The $600 million revolving credit facility had $537.0 million drawn and $63.0 million available. Long-term debt, net of current maturities and fees, was $230.9 million; current maturities were $16.8 million. Debt under the revolving facility is variable-rate and unhedged. Operating lease liabilities were $2.24 billion, reflecting PACS’s reliance on leased facilities. The company reported compliance with its credit facility covenants.
Changes, operating drivers and cash flow
- Revenue growth principally reflected expansion: skilled nursing operational beds increased by 5,194 year over year, and patient days rose 35.3%. Occupancy was 91.1%, versus 91.8%.
- Payor mix shifted toward Medicaid: Medicaid accounted for 38.8% of patient and resident service revenue, versus 30.3%; Medicare accounted for 35.7%, versus 48.1%. Overall skilled mix by revenue declined to 52.0% from 63.7%.
- For mature facilities, occupancy improved to 94.6% from 93.2%. New facilities had 83.3% occupancy versus 90.8%, and their skilled mix by revenue was 38.4% versus 62.4%. Management reports that acquired facilities are often underperforming and require a transition period.
- Q1 expansion added 10 stand-alone facilities and six real estate properties for an aggregate purchase price of $79.0 million, adding 1,334 skilled nursing beds and 174 assisted living beds. Acquisition and property spending in investing cash flow was $78.5 million.
- Operating cash flow declined amid working-capital needs, including a $74.9 million increase in accounts receivable. Days sales outstanding increased to 57.3 from 52.7, which management attributes mainly to newly acquired facilities and longer collection periods during ownership transitions. Investing activities used $118.7 million; financing activities provided $34.5 million.
Outlook, unusual items and principal risks
- Management says cash, operating cash flow, available borrowing capacity and IPO proceeds are expected to cover operating needs for at least the next 12 months. The filing gives no specific revenue or earnings guidance.
- The April 15, 2024 IPO generated $423.0 million of net proceeds. The company reports using approximately $370.0 million in the credit facility note and approximately $371.4 million in MD&A to repay facility borrowings; it also describes subsequent draws and payments that left $180.0 million drawn and $420.0 million available as of the filing date. These reported payoff amounts differ and should be reconciled.
- The company anticipates higher public-company costs and stock-based compensation beginning in Q2 2024. It says it expects to retain future earnings and does not anticipate cash dividends for the foreseeable future; Q1 dividends were $17.5 million.
- Key business risks include reliance on Medicare, Medicaid and other payors; reimbursement and patient-acuity changes; labor availability, costs and minimum staffing requirements; regulatory reviews and billing audits; clinical quality, litigation and self-insurance exposure; acquisition integration; and the concentration of approximately 64% of skilled nursing beds in California.
- The $36.5 million reserve for Employee Retention Tax Credits reflects uncertainty over whether previously claimed credits must be repaid, potentially with penalties. The company also reported two facilities with special focus facility status and ongoing ordinary-course litigation and regulatory matters; management does not believe these matters are likely to have a material adverse effect, but outcomes remain uncertain.
- Corporate governance and ownership warrant attention: founders collectively retained substantial voting control after the IPO, and the company may rely on NYSE controlled-company exemptions. The filing also identifies possible founder margin loans secured by shares and potential selling pressure when lock-ups expire.
Important facts for investors to verify
- Reconcile the $370.0 million versus $371.4 million reported IPO debt repayment amounts and confirm the post-transaction credit facility balance and availability.
- Track receivables, days sales outstanding and operating cash flow to assess whether acquisition-related collection delays persist.
- Monitor payor mix, skilled mix and occupancy, particularly performance of newly acquired facilities and the effects of Medicaid reimbursement and staffing costs.
- Assess exposure to variable SOFR rates, lease commitments, self-insurance reserves, litigation and the ERTC reserve.
- Review implementation of federal and state staffing rules, facility survey outcomes, and the effects of concentrated California operations.
- Evaluate IPO-related dilution and stock compensation, founder control and pledged-share risk, and the company’s stated expectation not to pay dividends in the foreseeable future.